Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,493 | 721 | 99.9% |
| Consulting Fee | $14.99 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $3,706 | 227 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,901 | 106 | $0 (2024) |
| Gilead Sciences, Inc. | $1,387 | 36 | $0 (2024) |
| Janssen Biotech, Inc. | $920.88 | 51 | $0 (2024) |
| Merck Sharp & Dohme LLC | $622.96 | 34 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $567.63 | 34 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $567.18 | 13 | $0 (2024) |
| Allergan, Inc. | $446.45 | 30 | $0 (2020) |
| IRONWOOD PHARMACEUTICALS, INC | $437.78 | 26 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $325.95 | 15 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,814 | 100 | ABBVIE INC. ($814.98) |
| 2023 | $2,227 | 106 | AbbVie Inc. ($589.60) |
| 2022 | $2,026 | 108 | ABBVIE INC. ($781.51) |
| 2021 | $1,143 | 65 | AbbVie Inc. ($381.60) |
| 2020 | $833.67 | 49 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($281.10) |
| 2019 | $1,349 | 75 | AbbVie, Inc. ($315.94) |
| 2018 | $1,819 | 105 | AbbVie, Inc. ($400.84) |
| 2017 | $2,295 | 114 | Intercept Pharmaceuticals, Inc. ($478.04) |
All Payment Transactions
722 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: Rare Disease | ||||||
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/19/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/09/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $127.62 | General |
| Category: Immunology | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: Gastroenterology | ||||||
| 11/25/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $20.68 | General |
| Category: LIVER DISEASE | ||||||
| 11/22/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $19.69 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $8.94 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $14.43 | General |
| Category: Immunology | ||||||
| 11/13/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $5.20 | General |
| Category: VIROLOGY | ||||||
| 11/12/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $4.33 | General |
| Category: VIROLOGY | ||||||
| 11/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.25 | General |
| 10/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/29/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: Immunology | ||||||
| 10/26/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $19.16 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/24/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $20.30 | General |
| Category: Immunology | ||||||
| 10/23/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $12.58 | General |
| Category: IMMUNOLOGY | ||||||
| 10/22/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $17.84 | General |
| Category: GI | ||||||
| 10/18/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/17/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $6.60 | General |
| Category: VIROLOGY | ||||||
| 10/17/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $4.68 | General |
| Category: VIROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 620 | 759 | $377,362 | $81,384 |
| 2022 | 17 | 705 | 830 | $459,806 | $94,307 |
| 2021 | 16 | 840 | 1,002 | $459,010 | $107,643 |
| 2020 | 18 | 970 | 1,222 | $514,050 | $125,619 |
All Medicare Procedures & Services
64 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 72 | 72 | $67,896 | $14,306 | 21.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 116 | 151 | $59,192 | $13,100 | 22.1% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2023 | 23 | 45 | $60,477 | $11,920 | 19.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 81 | 157 | $32,970 | $9,456 | 28.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 70 | 70 | $28,000 | $6,938 | 24.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 44 | 46 | $27,600 | $4,465 | 16.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 22 | 22 | $16,434 | $3,813 | 23.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 56 | 59 | $16,221 | $3,707 | 22.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $16,224 | $3,429 | 21.1% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 39 | 39 | $15,912 | $3,319 | 20.9% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 19 | 20 | $14,940 | $3,257 | 21.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 33 | 33 | $11,187 | $2,250 | 20.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 13 | 13 | $10,309 | $1,424 | 13.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 95 | 96 | $90,528 | $18,598 | 20.5% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2022 | 29 | 56 | $92,088 | $16,375 | 17.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 89 | 103 | $40,376 | $8,874 | 22.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 68 | 135 | $28,350 | $7,362 | 26.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 56 | 56 | $28,392 | $6,142 | 21.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 88 | 95 | $26,220 | $5,641 | 21.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 30 | 30 | $22,410 | $5,299 | 23.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 51 | 52 | $20,800 | $5,175 | 24.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 40 | 40 | $24,000 | $3,540 | 14.8% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 37 | 37 | $15,096 | $3,180 | 21.1% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 16 | 16 | $11,952 | $2,829 | 23.7% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 18 | 19 | $14,193 | $2,530 | 17.8% |
About Dr. Ryan Wanamaker, MD
Dr. Ryan Wanamaker, MD is a Gastroenterology healthcare provider based in Savannah, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1326090358.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ryan Wanamaker, MD has received a total of $13,508 in payments from pharmaceutical and medical device companies, with $1,814 received in 2024. These payments were reported across 722 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($13,493).
As a Medicare-enrolled provider, Wanamaker has provided services to 3,135 Medicare beneficiaries, totaling 3,813 services with total Medicare billing of $408,953. Data is available for 4 years (2020–2023), covering 64 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Savannah, GA
- Active Since 05/17/2006
- Last Updated 02/13/2015
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1326090358
Products in Payments
- XIFAXAN (Drug) $1,372
- RINVOQ (Biological) $1,059
- Vemlidy (Drug) $683.13
- STELARA (Biological) $547.84
- DIFICID (Drug) $518.38
- Humira (Biological) $503.78
- LINZESS (Drug) $483.46
- OCA (Drug) $478.04
- HUMIRA (Biological) $457.56
- TRULANCE (Drug) $449.16
- SKYRIZI (Biological) $383.59
- VIBERZI (Drug) $379.43
- MAVYRET (Drug) $343.17
- REMICADE (Biological) $290.39
- Linzess (Drug) $284.48
- ENTYVIO (Biological) $268.64
- DUPIXENT (Biological) $264.59
- CREON (Drug) $242.99
- ZENPEP (Drug) $199.10
- Entyvio (Biological) $187.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Savannah
Dr. Daniel Mullady, Md, MD
Gastroenterology — Payments: $119,628
George Aragon, Md, MD
Gastroenterology — Payments: $17,588
Travis Wiggins, M.d, M.D
Gastroenterology — Payments: $17,255
Dr. John Northup, M.d, M.D
Gastroenterology — Payments: $14,252
Mark Nyce, Md, MD
Gastroenterology — Payments: $10,771
Charles Duckworth, Md, MD
Gastroenterology — Payments: $10,269